Neuroprotective agents for clinical trials in ALS: a systematic assessment

Area of Science:

• Neuroscience
• Pharmacology
• Drug Discovery

Background:

• Riluzole is the sole FDA-approved drug for ALS, offering limited survival benefits.
• There is a critical need for novel neuroprotective agents to improve ALS patient outcomes.

Purpose of the Study:

• To identify and evaluate potential neuroprotective drugs for amyotrophic lateral sclerosis (ALS).
• To determine data requirements for advancing candidate drugs into phase III clinical trials.

Main Methods:

• A comprehensive literature review and expert consultation identified 113 compounds tested in ALS animal models and patients.
• Initial screening narrowed the list to 24 agents based on scientific rationale, toxicity, and prior study efficacy.
• Detailed pharmacologic evaluation was conducted on the 24 selected drugs.

Main Results:

• Twenty drugs were deemed suitable for further ALS treatment development.
• Talampanel and tamoxifen showed preliminary efficacy in early trials.
• Ceftriaxone, minocycline, ONO-2506, and IGF-1 polypeptide are in ongoing phase III ALS trials.
• Several other agents require additional preclinical and human data, including CNS penetration, before phase III trials.

Conclusions:

• Multiple neuroprotective compounds with diverse mechanisms show promise for ALS.
• Further investigation of these agents is warranted to develop new ALS therapies.